Abstract
Aim: Eltrombopag and romiplostim are comparable second-line therapies in chronic immune thrombocytopenia. Treatment decisions are made in different contexts. A framework was created to outline decision pathways for physicians and payers. Materials & methods: The costs of drugs, administration, routine care, bleeding, other adverse events and mortality were included in the year-long calculation of total costs from a US private payer perspective. Treatment parameters and outcome data were obtained from relevant clinical trials. Results: The total cost per year, per patient of eltrombopag was US$51,000 versus US$76,000 for romiplostim. Drug costs and costs associated with bleeding-related events were the main drivers of cost difference. Conclusion: This framework facilitates decision-making in the management of chronic immune thrombocytopenia with eltrombopag and romiplostim.
Keywords:
costs; eltrombopag; immune thrombocytopenia; romiplostim; thrombopoietin receptor agonist.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Benzoates / adverse effects
-
Benzoates / economics
-
Benzoates / therapeutic use*
-
Chronic Disease
-
Clinical Decision-Making
-
Cost-Benefit Analysis
-
Costs and Cost Analysis
-
Decision Support Techniques*
-
Drug Costs
-
Hemorrhage / chemically induced
-
Humans
-
Hydrazines / adverse effects
-
Hydrazines / economics
-
Hydrazines / therapeutic use*
-
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
-
Pyrazoles / adverse effects
-
Pyrazoles / economics
-
Pyrazoles / therapeutic use*
-
Receptors, Fc / therapeutic use*
-
Receptors, Thrombopoietin / agonists*
-
Recombinant Fusion Proteins / adverse effects
-
Recombinant Fusion Proteins / economics
-
Recombinant Fusion Proteins / therapeutic use*
-
Thrombopoietin / adverse effects
-
Thrombopoietin / economics
-
Thrombopoietin / therapeutic use*
-
United States
Substances
-
Benzoates
-
Hydrazines
-
Pyrazoles
-
Receptors, Fc
-
Receptors, Thrombopoietin
-
Recombinant Fusion Proteins
-
Thrombopoietin
-
romiplostim
-
eltrombopag